PSA Cut-Point Indicates When to Start Salvage Radiotherapy in Prostate Cancer


An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.

At the 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®), CancerNetwork® spoke with Anthony V. D’Amico, MD, PhD, about data from a study investigating the impact of prostate-specific antigen (PSA) level on the risk of recurrence or death when starting salvage radiotherapy for prostate cancer.

Investigators identified an increased risk of mortality among patients with at most 1 high-risk factor who initiated salvage radiotherapy with a PSA level of over 0.25 ng/mL vs patients whose level was 0.25 ng/mL or less (adjusted hazard ratio [aHR], 1.49; 95% CI, 1.11-2.00; P = .008).

D’Amico, a professor and chair of genitourinary radiation oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, stated that treatment should begin for patients with 1 high-risk factor before their PSA reaches 0.25 ng/ml, and that adjuvant therapy should start for those with 2 risk factors before their PSA levels begin to increase further.


For people with a single risk factor, it appears that there is a PSA cut point above which the risk of death increases by 50%, and below which it does not. That cut point is 0.25 ng/mL in terms of the PSA level. It appears for people who have a single risk factor; a Gleason score of 8, 9, or 10; or cancer extending beyond the prostate at the time of surgery—pT3 or pT4—that establishing salvage therapy by a PSA of 0.25 would be important.

The reason why this is timely is because with the advent of advanced imaging, PSMA PET technology, many physicians are waiting to start salvage radiation to a higher PSA level, typically 0.3 ng/mL or sometimes as high as 0.5 ng/mL because of 2 reasons: One, not all insurers will reimburse the PSMA PET at low PSA levels. Some do, but many don't. And second, the performance characteristics of the PET scan improve with increasing PSA level.

At [Dana-Farber Cancer Institute], we've adopted the policy of starting salvage therapy in patients with a single high-risk factor before the PSA gets to 0.2 ng/mL, certainly not 0.25 ng/mL. That's an important point to take home—that for one risk factor, [start treatment] at 0.25 ng/mL, and for 2 risk factors, [use] adjuvant [therapy] and don’t wait for the PSA to rise.


Tilki D, Chen M, Wu J, et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. Published online March 1, 2023. Doi:10.1200/JCO.22.02489

Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Related Content